• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双脱氧核苷类抗逆转录病毒药物临床药代动力学概述

Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents.

作者信息

Burger D M, Meenhorst P L, Beijnen J H

机构信息

Department of Pharmacy, Slotervaart Hospital, Amsterdam, The Netherlands.

出版信息

Pharm World Sci. 1995 Mar 24;17(2):25-30. doi: 10.1007/BF01875051.

DOI:10.1007/BF01875051
PMID:7795555
Abstract

In this paper aspects of the clinical pharmacokinetics of the antiretroviral agents zidovudine, didanosine and zalcitabine are reviewed. Special attention is paid to possibly altered pharmacokinetics in special circumstances, such as hepatic and renal dysfunction, pregnancy, stage of disease, etc. The dideoxynucleoside antiretroviral agents have some clinical pharmacokinetic properties in common (rapid absorption and elimination), but substantial differences exist in their degree of absorption, metabolism and penetration into the cerebrospinal fluid. All agents display wide interpatient variability in pharmacokinetic parameters. The relevance of therapeutic drug monitoring of antiretroviral agents is also discussed.

摘要

本文综述了抗逆转录病毒药物齐多夫定、去羟肌苷和扎西他滨的临床药代动力学方面。特别关注特殊情况下(如肝肾功能不全、妊娠、疾病阶段等)可能改变的药代动力学。双脱氧核苷类抗逆转录病毒药物具有一些共同的临床药代动力学特性(吸收和消除迅速),但在吸收程度、代谢及脑脊液渗透方面存在显著差异。所有药物的药代动力学参数在患者间均表现出很大的变异性。本文还讨论了抗逆转录病毒药物治疗药物监测的相关性。

相似文献

1
Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents.双脱氧核苷类抗逆转录病毒药物临床药代动力学概述
Pharm World Sci. 1995 Mar 24;17(2):25-30. doi: 10.1007/BF01875051.
2
Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.嘌呤和嘧啶衍生物的抗逆转录病毒作用的代谢与机制
Pharm World Sci. 1994 Apr 15;16(2):113-26. doi: 10.1007/BF01880662.
3
Clinical pharmacokinetics of nucleoside antiretroviral agents.
J Infect Dis. 1995 Mar;171 Suppl 2:S99-112. doi: 10.1093/infdis/171.supplement_2.s99.
4
Didanosine, a new antiretroviral drug. A review.
Pharm Weekbl Sci. 1992 Oct 16;14(5):297-304. doi: 10.1007/BF01977617.
5
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides.叠氮胸苷及相关的2',3'-双脱氧核苷对新鲜的和培养的人外周血单核细胞/巨噬细胞中人类免疫缺陷病毒(HIV-1/HTLV-IIIBa-L)复制的抑制作用
J Exp Med. 1988 Sep 1;168(3):1111-25. doi: 10.1084/jem.168.3.1111.
6
The antiretroviral and cytostatic activity, and metabolism of 3'-azido-2',3'-dideoxythymidine, 3'-fluoro-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly cell type-dependent.
Adv Exp Med Biol. 1989;253B:407-13. doi: 10.1007/978-1-4684-5676-9_60.
7
Comparative pharmacokinetics of antiviral nucleoside analogues.抗病毒核苷类似物的比较药代动力学
Clin Pharmacokinet. 1993 Feb;24(2):101-23. doi: 10.2165/00003088-199324020-00002.
8
The antiviral activity of dideoxycytidine.
J Antimicrob Chemother. 1989 Jan;23 Suppl A:29-34. doi: 10.1093/jac/23.suppl_a.29.
9
Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.艾滋病及相关疾病患者中2',3'-双脱氧胞苷的药代动力学
J Clin Pharmacol. 1988 Sep;28(9):837-42. doi: 10.1002/j.1552-4604.1988.tb03225.x.
10
Comparative pharmacokinetics of new anti-HIV agents: 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine.新型抗艾滋病病毒药物的比较药代动力学:2',3'-双脱氧腺苷和2',3'-双脱氧肌苷
Biochem Pharmacol. 1989 May 1;38(9):1385-8. doi: 10.1016/0006-2952(89)90176-7.

引用本文的文献

1
Neuropsychiatric Effects of HIV Antiviral Medications.HIV抗病毒药物的神经精神效应
Drug Saf. 2016 Oct;39(10):945-57. doi: 10.1007/s40264-016-0440-y.
2
Clinical implications of CNS penetration of antiretroviral drugs.抗逆转录病毒药物穿透中枢神经系统的临床意义。
CNS Drugs. 2002;16(9):595-609. doi: 10.2165/00023210-200216090-00002.
3
Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.齐多夫定治疗的药代动力学个体化。药代动力学-药效学关系的现状。

本文引用的文献

1
Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome.
Clin Pharmacol Ther. 1993 May;53(5):529-35. doi: 10.1038/clpt.1993.66.
2
Comparative pharmacokinetics of antiviral nucleoside analogues.抗病毒核苷类似物的比较药代动力学
Clin Pharmacokinet. 1993 Feb;24(2):101-23. doi: 10.2165/00003088-199324020-00002.
3
Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus.对出生时暴露于人类免疫缺陷病毒的婴儿给予齐多夫定的I期评估。
Clin Pharmacokinet. 1996 Apr;30(4):314-27. doi: 10.2165/00003088-199630040-00004.
J Pediatr. 1993 Jan;122(1):137-44. doi: 10.1016/s0022-3476(05)83507-3.
4
Transfer and metabolism of dideoxyinosine by the perfused human placenta.
J Acquir Immune Defic Syndr (1988). 1993 Jan;6(1):2-6.
5
2',3'-dideoxyinosine (ddI): its chemical stability and cyclodextrin complexation in aqueous media.2',3'-双脱氧肌苷(ddI):其在水性介质中的化学稳定性及与环糊精的络合作用
J Pharm Biomed Anal. 1993 Jun;11(6):489-93. doi: 10.1016/0731-7085(93)80162-t.
6
Therapy for human immunodeficiency virus infection.人类免疫缺陷病毒感染的治疗
N Engl J Med. 1993 Jun 10;328(23):1686-95. doi: 10.1056/NEJM199306103282307.
7
Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.齐多夫定与去羟肌苷联合治疗与齐多夫定单药治疗在HIV-1感染中的比较。
Ann Intern Med. 1993 Oct 15;119(8):786-93. doi: 10.7326/0003-4819-119-8-199310150-00003.
8
Metabolism of didanosine (ddI) by erythrocytes: pharmacokinetic implications.红细胞对去羟肌苷(ddI)的代谢:药代动力学意义。
Br J Clin Pharmacol. 1993 Jul;36(1):87-8. doi: 10.1111/j.1365-2125.1993.tb05899.x.
9
Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV.齐多夫定在感染人类免疫缺陷病毒患者脑脊液中的渗透情况。
AIDS. 1993 Dec;7(12):1581-7. doi: 10.1097/00002030-199312000-00006.
10
Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS.标准早餐对艾滋病患者口服齐多夫定药代动力学的影响。
Antimicrob Agents Chemother. 1993 Oct;37(10):2153-8. doi: 10.1128/AAC.37.10.2153.